📊 Technical Analysis
- UNH recently hit both a 1-year low and 5-year low, bottoming around the $310 zone.
- Daily chart shows:
- MACD bullish crossover → early uptrend signal.
- RSI recovery to ~65 → no longer oversold, but nearing neutral-bullish territory.
- Short-term resistance: $350.
- Longer-term resistance: $375–$400.
- Volume: Heavy selling in May–June looked like capitulation; current rally is lighter but steady.
- Multi-year uptrend broke down in 2024–2025, with UNH now trading at a multi-year support base (~$310).
- Weekly MACD still negative but flattening, suggesting selling pressure has slowed.
- Weekly RSI lifted from oversold (~33) to neutral (~42).
✅ Conclusion: Technicals suggest UNH may be forming a long-term base, with upside potential if $350–$375 breaks.
💵 Fundamentals
- Market Cap: $285.6B — remains a healthcare giant.
- Valuation:
- P/E: 13.4 (below sector average ~18).
- P/FCF: 11.2 → attractive vs. history.
- Profitability:
- Net margin: 5% (thin, but typical for insurers).
- ROE: 23% (excellent efficiency).
- ROIC: 13%, comfortably above estimated WACC (~8–9%).
- Cash Flow:
- Free cash flow (TTM): $25.3B → more than enough to fund dividends and debt.
- Debt-to-equity: 0.84 → healthy leverage.
- Dividends:
- Yield: 2.8%, payout ratio ~37% → safe and growing.
✅ Conclusion: UNH fundamentals are solid, with massive cash flow support, undervalued multiples, and a safe dividend — making it a defensive yet attractive long-term play.
🧾 Analyst Price Targets
- Range: $198 (Baird, bearish) → $390 (Wolfe Research, bullish).
- Median: ~$355 → ~13% upside from $315 current.
- Barclays (Sept 2025): Raised PT to $362 (bullish).
- Multiple firms (UBS, Piper, Mizuho) trimmed targets but still above current levels.
- Analysts slashed PTs heavily from prior $500–$600, signaling a reset of expectations.
✅ Conclusion: Wall Street is cautiously bullish — consensus sees moderate recovery, not a return to old highs soon.
🕵️ Insider & Political Trading
- Executives/Directors:
- CFO DeVeydt and multiple directors awarded stock grants — but no significant open-market buying.
- Neutral signal.
- Senate Disclosures:
- More sales than buys in 2025 (Whitehouse, Mullin, King).
- Slightly bearish.
- House Disclosures:
- More purchases in mid–2025 (McCaul, Greene, Cisneros, McClain).
- Mildly bullish.
✅ Conclusion: Insiders aren’t aggressively buying, but Congressional trades lean mixed-to-positive, suggesting some confidence at these depressed levels.
🎯 Options Strategy — LEAPS Volatility Capture
- Setup: Buy UNH $350 Call, ~500 DTE (LEAPS).
- Delta: ~0.45 → balanced exposure (moves ~45% of stock price).
- Vega: Highest in range → most sensitive to IV expansion.
- Theta: Minimal (long-dated option).
- Liquidity: Sufficient open interest at $350 strike.
Rationale:
- $350 is a major resistance zone; if UNH rallies into it, option value surges.
- Even if stock stays near $315, vega expansion before earnings inflates option premium.
- Exit Plan: Sell to close 1 day before earnings to capture IV expansion and avoid post-earnings IV crush.
✅ Conclusion: Smart LEAPS play — leverages both directional upside + volatility mechanics, with defined risk.
🧱 12-Pillar Hedge Fund Framework Summary
- Revenue Growth: Stable, low-single-digit growth.
- Earnings Growth: EPS ~$23, still solid despite pullback.
- Free Cash Flow: $25B+, excellent.
- Margins: Thin but industry-normal.
- ROE/ROIC: Very strong.
- Insider/Institutional: Institutions dominate; insiders neutral.
- Technical Strength: Base forming, MACD bullish crossover.
- Analyst Sentiment: Cautiously bullish, median PT ~$355.
- Options Flow: Favorable LEAPS setup at $350 strike.
- Moat: Strongest in healthcare insurance (UHC + Optum).
- Catalysts: Next earnings, policy/regulation shifts.
- Valuation: Attractive relative to history.
✅ Overall Thesis: UNH at ~$315 looks like a long-term accumulation opportunity. For traders, the $350 LEAPS call offers an efficient way to capture volatility + recovery upside.
